Study to Assess the Effect of Multistrain Probiotic on the Immune Response to the Influenza Vaccination - Trial NCT06103994
Access comprehensive clinical trial information for NCT06103994 through Pure Global AI's free database. This phase not specified trial is sponsored by The Archer-Daniels-Midland Company and is currently Recruiting. The study focuses on Influenza. Target enrollment is 115 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The Archer-Daniels-Midland Company
Timeline & Enrollment
N/A
Oct 27, 2023
Mar 01, 2024
Primary Outcome
Change in serum strain-specific geometric mean antibody titers (determined by hemagglutination inhibition [HAI] tests)
Summary
A randomized, triple-blinded, placebo-controlled, parallel group study, to assess the effect
 of multistrain probiotic on the immune response to the Influenza vaccination
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06103994
Non-Device Trial